← Leaderboards
Robert Wi Chen
Beckman Research Institute/City Of Hope
$1,186,185
Attributed
$1,186,185
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $326K · FY2019–22$500K$375K$250K$125K$0
'19
'20
'21
'22
Funding mix
By agency
NIH$1,186,185 · 1
By mechanism
P50$1,186,185 · 1
Top collaborators
No co-investigators on record.
Most similar at Beckman Research Institute/City Of Hope
Same institution · by research overlap
- Jeffrey Y Wong$4,970,582
- Guido Marcucci$19,718,636
- Jianjun Chen$21,393,583
- Susanta K Hui$5,584,345
- Jana Portnow$3,811,944
Others in their field
Other Emerging Leaders on “Anti-Pd-1”
- John Freymann · Leidos Biomedical Research, Inc.$5,261,900
- Tina Garyantes · Linnaeus Therapeutics, Llc$5,000,000
- Amaia Lujambio · Icahn School Of Medicine At Mount Sinai$4,251,878
- Alexander Huang · University Of Pennsylvania$3,639,634
- Yuliya Pylayeva-Gupta · Univ Of North Carolina Chapel Hill$3,602,417
- Jun Wang · New York University School Of Medicine$3,408,076
Research focus
Anti-Pd-1Anti-Pd1 AntibodiesAra-CAutologousBaseBasiliximabBiometryBiopsyCarboplatinCareerCarmustineCd25 AntigensCellsChemotherapyCitiesClinical TrialsColorCombination Drug TherapyConditioningCorrelative StudyDensityDesignDifferential ExpressionAntibodies
Grant awards (4)
Targeted immunotherapy for relapsed/refractory Hodgkin lymphoma$272,491
P50 · FY2022 · CA · contact PI
Targeted immunotherapy for relapsed/refractory Hodgkin lymphoma$320,777
P50 · FY2021 · CA · contact PI
Targeted immunotherapy for relapsed/refractory Hodgkin lymphoma$266,884
P50 · FY2020 · CA · contact PI
Targeted immunotherapy for relapsed/refractory Hodgkin lymphoma$326,033
P50 · FY2019 · CA · contact PI